Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||6MHP vaccine + CDX-1140 + NeoAg-mBRAF + Poly ICLC|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|6MHP vaccine||6MHP vaccine is a peptide vaccine containing 6 melanoma helper peptides as epitopes, which may stimulate TH1-biased immune response against tumor cells expressing these antigens (PMID: 25126421, PMID: 26258314).|
|CDX-1140||CDX 1140|CDX1140||CD40 Antibody 13||CDX-1140 is an antibody that binds CD40 and activates signaling, potentially resulting in enhanced anti-tumor immune response (Blood, 128(22), 1848, PMID: 30382327).|
|NeoAg-mBRAF||NeoAg mBRAF|BRAF 585-614 (V600E)|BRAF585-614-V600E|BRAF 585-614 V600E||NeoAg-mBRAF is a peptide consisting of aa 585-614 of the Braf protein with the BRAF V600E mutation, which may lead to cytotoxic T-lymphocyte mediated immune response against BRAF V600E-expressing tumor cells (NCI Drug Dictionary).|
|Poly ICLC||Hiltonol||Hiltonol (poly ICLC) is a synthetic double stranded RNA complex, which induces interferon production and stimulates anti-tumor immune response (PMID: 22126373).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04364230||Phase Ib/II||6MHP vaccine + CDX-1140 + NeoAg-mBRAF + Poly ICLC||Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Mel66)||Recruiting||USA||0|